Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
55.13
-2.24 (-3.90%)
Nov 15, 2024, 4:00 PM EST - Market closed
Revolution Medicines Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for RVMD stock have an average target of 57, with a low estimate of 30 and a high estimate of 82. The average target predicts an increase of 3.39% from the current stock price of 55.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RVMD stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 6 | 6 |
| Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $61 → $68 | Strong Buy | Maintains | $61 → $68 | +23.34% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $62 → $64 | Strong Buy | Maintains | $62 → $64 | +16.09% | Nov 7, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $54 → $63 | Buy | Maintains | $54 → $63 | +14.28% | Nov 7, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $57 → $70 | Buy | Maintains | $57 → $70 | +26.97% | Nov 7, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $72 → $82 | Strong Buy | Maintains | $72 → $82 | +48.74% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
306.00K
from 11.58M
Decreased by -97.36%
Revenue Next Year
1.22M
from 306.00K
Increased by 300.00%
EPS This Year
-3.51
from -3.86
EPS Next Year
-4.13
from -3.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.7M | 18.9M | 154.1M | ||
| Avg | 306,000 | 1.2M | 17.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -59.2% | 6,076.5% | 12,493.1% | ||
| Avg | -97.4% | 300.0% | 1,301.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.54 | -3.35 | -2.91 | ||
| Avg | -3.51 | -4.13 | -4.34 | ||
| Low | -3.47 | -4.56 | -4.60 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.